23,204 Shares in 10x Genomics $TXG Purchased by TriaGen Wealth Management LLC

by · The Cerbat Gem

TriaGen Wealth Management LLC purchased a new stake in shares of 10x Genomics (NASDAQ:TXG – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund purchased 23,204 shares of the company’s stock, valued at approximately $378,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TXG. Vanguard Group Inc. lifted its stake in 10x Genomics by 6.7% in the third quarter. Vanguard Group Inc. now owns 13,274,332 shares of the company’s stock worth $155,177,000 after purchasing an additional 834,272 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of 10x Genomics by 2.1% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 5,492,189 shares of the company’s stock valued at $89,578,000 after buying an additional 110,970 shares during the last quarter. Millennium Management LLC grew its stake in shares of 10x Genomics by 84.7% during the third quarter. Millennium Management LLC now owns 5,437,969 shares of the company’s stock valued at $63,570,000 after buying an additional 2,494,142 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of 10x Genomics by 126.6% in the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company’s stock worth $50,099,000 after buying an additional 2,394,355 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of 10x Genomics by 241.3% in the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock worth $47,916,000 after buying an additional 2,925,372 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,826 shares of 10x Genomics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $18.58, for a total value of $145,407.08. Following the completion of the sale, the insider directly owned 424,779 shares in the company, valued at $7,892,393.82. The trade was a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Adam Taich sold 8,968 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $18.58, for a total transaction of $166,625.44. Following the completion of the sale, the chief financial officer directly owned 288,417 shares of the company’s stock, valued at approximately $5,358,787.86. This trade represents a 3.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 46,426 shares of company stock worth $902,695 over the last three months. 10.03% of the stock is owned by corporate insiders.

10x Genomics Price Performance

TXG opened at $26.08 on Monday. The stock’s fifty day moving average is $20.69 and its two-hundred day moving average is $18.09. The company has a market capitalization of $3.33 billion, a P/E ratio of -74.51 and a beta of 2.17. 10x Genomics has a 52 week low of $7.25 and a 52 week high of $26.45.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its earnings results on Thursday, February 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.06. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The business had revenue of $166.03 million during the quarter, compared to analysts’ expectations of $160.35 million. During the same period in the prior year, the business earned ($0.40) EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TXG shares. Barclays boosted their price objective on 10x Genomics from $22.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, April 14th. William Blair upgraded 10x Genomics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 31st. Canaccord Genuity Group set a $22.00 target price on shares of 10x Genomics in a research note on Friday, February 13th. TD Cowen upped their price target on shares of 10x Genomics from $18.00 to $19.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Finally, Citigroup raised their price target on shares of 10x Genomics from $18.00 to $24.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.46.

Get Our Latest Stock Report on 10x Genomics

About 10x Genomics

(Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.

Read More

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG – Free Report).